Contrasting Acumen Pharmaceuticals (NASDAQ:ABOS) and Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics (NASDAQ:JSPR) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings for Jasper Therapeutics and Acumen Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	0	0	10	0	3.00
Acumen Pharmaceuticals	0	0	3	1	3.25

Jasper Therapeutics currently has a consensus target price of $73.00, indicating a potential upside of 287.68%. Acumen Pharmaceuticals has a consensus target price of $9.00, indicating a potential upside of 262.90%. Given Jasper Therapeutics’ higher possible upside, research analysts plainly believe Jasper Therapeutics is more favorable than Acumen Pharmaceuticals.

Profitability

This table compares Jasper Therapeutics and Acumen Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-64.68%	-56.10%
Acumen Pharmaceuticals	N/A	-24.63%	-21.87%

Valuation and Earnings

This table compares Jasper Therapeutics and Acumen Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$64.46 million	($5.63)	-3.34
Acumen Pharmaceuticals	N/A	N/A	-$52.37 million	($1.06)	-2.34

Jasper Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

79.8% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 2.7% of Jasper Therapeutics shares are held by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Jasper Therapeutics has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500.

Summary

Acumen Pharmaceuticals beats Jasper Therapeutics on 8 of the 12 factors compared between the two stocks.

About Jasper Therapeutics

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.